EA201692061A1 - Способы лечения гиперсомнии - Google Patents

Способы лечения гиперсомнии

Info

Publication number
EA201692061A1
EA201692061A1 EA201692061A EA201692061A EA201692061A1 EA 201692061 A1 EA201692061 A1 EA 201692061A1 EA 201692061 A EA201692061 A EA 201692061A EA 201692061 A EA201692061 A EA 201692061A EA 201692061 A1 EA201692061 A1 EA 201692061A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treatment
hypersomony
gaba
present
Prior art date
Application number
EA201692061A
Other languages
English (en)
Inventor
Линдон Лин
Original Assignee
Бэлэнс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бэлэнс Терапьютикс, Инк. filed Critical Бэлэнс Терапьютикс, Инк.
Publication of EA201692061A1 publication Critical patent/EA201692061A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способам, составам и схемам лечения гиперсомнии у субъекта. Например, способы по настоящему изобретению включают введение блокатора хлоридных каналов GABA. В некоторых вариантах осуществления настоящего изобретения блокатором хлоридных каналов GABAявляется пентилентетразол (PTZ).
EA201692061A 2014-04-15 2015-04-14 Способы лечения гиперсомнии EA201692061A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979918P 2014-04-15 2014-04-15
PCT/US2015/025696 WO2015160766A1 (en) 2014-04-15 2015-04-14 Methods for treating hypersomnia

Publications (1)

Publication Number Publication Date
EA201692061A1 true EA201692061A1 (ru) 2017-03-31

Family

ID=54324484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692061A EA201692061A1 (ru) 2014-04-15 2015-04-14 Способы лечения гиперсомнии

Country Status (12)

Country Link
US (3) US10688103B2 (ru)
EP (1) EP3131904A4 (ru)
JP (2) JP6672264B2 (ru)
KR (1) KR20170005415A (ru)
CN (1) CN106459066B (ru)
AU (2) AU2015247829B2 (ru)
CA (1) CA2945705A1 (ru)
EA (1) EA201692061A1 (ru)
IL (1) IL248255A0 (ru)
MX (1) MX2016013340A (ru)
WO (1) WO2015160766A1 (ru)
ZA (1) ZA201607068B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
WO2018209119A1 (en) * 2017-05-10 2018-11-15 Emory University Treatment of conditions associated with myotonic dystrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137746A (ja) 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
WO2007139818A2 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
US20110038850A1 (en) 2007-01-05 2011-02-17 Didier Bagnol G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders
US9616070B2 (en) * 2008-03-12 2017-04-11 Emory University Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US8946206B2 (en) * 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
AU2012250776B2 (en) * 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives

Also Published As

Publication number Publication date
US20200360398A1 (en) 2020-11-19
US20180169107A1 (en) 2018-06-21
AU2019268190A1 (en) 2019-12-12
EP3131904A4 (en) 2017-11-22
KR20170005415A (ko) 2017-01-13
JP2017511386A (ja) 2017-04-20
AU2015247829B2 (en) 2019-12-05
CA2945705A1 (en) 2015-10-22
EP3131904A1 (en) 2017-02-22
US20230115839A1 (en) 2023-04-13
US10688103B2 (en) 2020-06-23
IL248255A0 (en) 2016-11-30
MX2016013340A (es) 2017-02-09
JP2020105200A (ja) 2020-07-09
CN106459066A (zh) 2017-02-22
WO2015160766A1 (en) 2015-10-22
CN106459066B (zh) 2020-07-07
JP6672264B2 (ja) 2020-03-25
ZA201607068B (en) 2023-01-25
AU2015247829A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
DK3297644T3 (da) Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201891251A1 (ru) Бициклические ингибиторы pad4
GEP20197046B (en) Substituted oxopyridine derivatives
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
NZ730603A (en) Mk2 inhibitors and uses thereof
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4